MERCK: European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial
Merck known as MSD outside the United States and Canada, announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the company’s Type II Variation, which seeks approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy (cisplatin or carboplatin) for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). Read More »